Cytokinetics, Incorporated $CYTK Shares Sold by FNY Investment Advisers LLC

FNY Investment Advisers LLC lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 77.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,000 shares of the biopharmaceutical company’s stock after selling 7,030 shares during the period. FNY Investment Advisers LLC’s holdings in Cytokinetics were worth $170,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC grew its holdings in Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in Cytokinetics in the 4th quarter worth $27,000. Kestra Advisory Services LLC acquired a new position in Cytokinetics in the 4th quarter worth $29,000. Quarry LP purchased a new position in Cytokinetics in the 3rd quarter valued at about $30,000. Finally, TD Waterhouse Canada Inc. purchased a new position in Cytokinetics in the 4th quarter valued at about $32,000.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Insider Activity

In other Cytokinetics news, CEO Robert I. Blum sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total value of $636,900.00. Following the completion of the sale, the chief executive officer directly owned 377,830 shares in the company, valued at $32,085,323.60. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B Lynne Parshall sold 5,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $74.08, for a total value of $370,400.00. Following the transaction, the director directly owned 15,784 shares of the company’s stock, valued at approximately $1,169,278.72. The trade was a 24.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 115,179 shares of company stock worth $9,126,054 over the last three months. Corporate insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CYTK shares. UBS Group raised Cytokinetics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $69.00 to $115.00 in a research report on Monday, June 29th. Royal Bank Of Canada reduced their price target on Cytokinetics from $117.00 to $112.00 and set an “outperform” rating for the company in a report on Friday. Wells Fargo & Company raised their price objective on Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Needham & Company LLC lifted their price objective on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a report on Friday. Finally, Mizuho upped their price target on shares of Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $100.85.

Cytokinetics Stock Down 5.7%

Shares of CYTK opened at $76.76 on Friday. The firm has a 50-day moving average price of $78.91 and a 200 day moving average price of $70.90. The firm has a market capitalization of $9.55 billion, a PE ratio of -10.63 and a beta of 0.38. Cytokinetics, Incorporated has a 52-week low of $32.89 and a 52-week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. During the same period in the previous year, the business posted ($1.12) EPS. The firm’s quarterly revenue was down 57.1% on a year-over-year basis. On average, equities analysts expect that Cytokinetics, Incorporated will post -6.2 EPS for the current year.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.